Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis

Kakeya, H.; Miyazaki, Y.; Senda, H.; Kobayashi, T.; Seki, M.; Izumikawa, K.; Yanagihara, K.; Yamamoto, Y.; Tashiro, T.; Kohno, S.

Antimicrobial Agents and ChemoTherapy 52(5): 1868-1870

2008


ISSN/ISBN: 1098-6596
PMID: 18299412
DOI: 10.1128/aac.01369-07
Accession: 022520599

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).